Funapide (INN) (former developmental code names TV-45070 and XEN402) is a novel analgesic under development by Xenon Pharmaceuticals (formerly in partnership with Teva Pharmaceutical Industries) for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain.

[1][2][3][4] It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker.

[1][2][4] Funapide is being evaluated in humans in both oral and topical formulations, and as of July 2014, has reached phase IIb clinical trials.

This analgesic-related article is a stub.

You can help Wikipedia by expanding it.